Searchable abstracts of presentations at key conferences in endocrinology

ea0026p247 | Pituitary | ECE2011

A multicenter study on acromegalic patients treated with pegvisomant monotherapy or with pegvisomant plus somatostatin analogues: role of exon 3 deleted GH receptor polymorfism

Filopanti Marcello , Olgiati Luca , Lania Andrea , Beck-Peccoz Paolo , De Marinis Laura , Grottoli Silvia , Martini Chiara , Cannavo Salvatore , Bogazzi Fausto , Ferone Diego , Arnaldi Giorgio , Peri Alessandro , Tita Patrizia , Pigliaru Francesca , Angeletti Gabriella , Jaffrain-Rea Marie-Lise , Losa Marco , Spada Anna

Introduction: To date, two pharmacogenetic studies investigated the effect of the common exon 3 deletion of GH receptor (d3-GHR) variant in small series of acromegalic patients treated with Pegvisomant (Peg), suggesting an association of d3-GHR allele with better response to Peg.Aim: To assess the influence of d3-GHR variant in a large cohort of acromegalics with active disease and resistance to somatostatin analogues (SSA) treated with either Peg monoth...